Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 262

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1B
Chunk 262
---
2024
     
    278,530

    $
    278,530

    42,323,759

    $
    42,324

    $
    125,397,691

    $
    (111,124,569
    )
     
    $
    14,593,976

F-8

TUHURA BIOSCIENCES, INC AND SUBSIDIARIESConsolidated statements of cash flowsFor the years ended December 31, 2024, and 2023  

    Years ended

    December 31,

    December 31,

    2024

    2023

    Cash flows from Operating activities:

    Net loss
     
    $
    (21,682,306
    )
     
    $
    (29,316,826
    )

    Adjustments to reconcile net loss to cash

    used in operating activities:

    Stock compensation expense

    1,958,663

    478,890

    Depreciation and amortization

    116,710

    177,377

    Write-off of in-process R&D

    -

    16,217,655

    Amortization of debt discount

    1,278,424

    5,124

    Change in fair value of derivative liability

    313,772

    -

    Changes in operating assets and liabilities:

    Other current assets

    (464,938
    )

    (1,995
    )

    Other noncurrent assets

    106,613

    151,173

    Accounts payable and accrued expenses

    3,644,924

    337,746

    Net cash flows from operating activities

    (14,728,138
    )

    (11,950,856
    )

    Cash flows from investing activities:

    Cash paid for asset acquisition

    -

    (1,217,655
    )

    Deposits, planned business acquisition

    (5,994,503
    )

    -

    Purchase of property and equipment

    (57,906
    )

    (79,224
    )

    Net cash flows from investing activities

    (6,052,409
    )

    (1,296,879
    )

    Cash flows from financing activities:

    Shares repurchased

    -

    (24,751
    )

    Proceeds from convertible notes payable